Filtered By:
Source: Mass Device
Management: Funding
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 62 results found since Jan 2013.
Silk Road touts TCAR study data
Silk Road Medical disclosed encouraging new clinical data for its Enroute device, which is cleared to help protect the brain from stroke while implanting a transcarotid artery stent.
The company said that additional data showed its Enroute transcarotid neuroprotection and stent system, indicated for transcarotid artery revascularization (TCAR), helped improve stroke and death rates in the wake of its FDA sign-off last October. Investigators from Massachusetts General Hospital and elsewhere presented their findings during the 2016 Vascular Annual Meeting of the Society for Vascular Surgery, which was held June 8-11 in Natio...
Source: Mass Device - June 15, 2016 Category: Medical Equipment Authors: Mark Hollmer Tags: Catheters Clinical Trials Stents Vascular Silk Road Medical Inc. Source Type: news
CardioNXT raises $1.5m for novel cardiac ablation tech
Heart focused medical-technology company CardioNXT said today it raised $1.5 million in equity funding to support its platform of cardiac arrhythmia products.
CardioNXT is developing products to improve the understanding of complex cardiac arrhythmias such as atrial fibrillation and to reduce the cost of cardiac catheter ablation procedures, the company said.
Funds in the round came from Solas BioVentures as well as existing investors in the Westminster, Colo.-based company.
“Our mission is to invest in solutions that enable people to lead longer and fuller lives. Atrial Fibrillation affects 6.1 million Americans a...
Source: Mass Device - May 25, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiovascular CardioNXT Source Type: news
Helius Medical closes over-allotment, brings round to $8.1 million
Helius Medical Technologies (OTC:HSDT) said yesterday it closed an over-allotment option for its most recent round of financing, bringing the total raised up to $8.1 million (CAD $10.3 million).
The Newton, Penn.-based company said it floated an additional 1.1 million units at 79¢ (CAD $1.00) in the over-allotment, raising an extra $857,083 for the round. The offering officially closed on April 18.
Each unit sold consisted of a Class A share and a half-share warrant with an exercise price of roughly $1.18 (C$1.50), the company said in a press release.
A commission of $51,424 was paid to Mackie Research Capital who acted...
Source: Mass Device - May 3, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Helius Medical Technologies Source Type: news
Helius Medical raises $7m for portable neuromodulation stimulator
Helius Medical Technologies (OTC:HSDT) said today that it raised $7.2 million (C$9.2 million) in a Canadian short-form offering and a concurrent private placement in the U.S.
Newtown, Pa.-based Helius said each unit of the offering had a Class A share and a half-share warrant with an exercise price of roughly $1.17 (C$1.50). The company also said it got the go-ahead to list its share on the Toronto stock exchange under the “HSM” symbol, starting today.
“This is a very meaningful development for our company. We are proud to qualify for listing on the TSX and we are very excited to have the resources to ...
Source: Mass Device - April 18, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Neuromodulation/Neurostimulation Wall Street Beat Helius Medical Technologies Source Type: news
Colibri Heart Valve looks to raise $25m Series C for TAVR device
Colibri Heart Valve is looking to raise a $25 million Series C for the ready-to-use replacement heart valve it’s developing and has already put $1.25 million into its coffers.
Broomfield, Colo.-based Colibri is running a 1st-in-human trial of the transcatheter aortic valve replacement it’s developing, a pre-mounted, pre-crimped and pre-packaged device that’s designed to be shipped ready to use, according to its website.
Colibri has said that patients enrolled in the study showed no observed stroke, no pacemaker implantations, virtually no paravalvular leak and a high retained average effective orifice ...
Source: Mass Device - March 29, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Replacement Heart Valves Wall Street Beat Colibri Heart Valve Source Type: news
Corvia Medical wins FDA nod for trial, inks exclusive buyout deal with strategic backer
Corvia Medical said today that it won an investigational device exemption from the FDA for a clinical trial of its cardiac implant designed to treat diastolic heart failure and inked a deal with an unnamed strategic investor that includes an exclusive buyout option.
Corvia’s transcatheter InterAtrial shunt device is designed to lower blood pressure in the left atrium and lungs by creating a small opening between the left and right atria, according to Corvia’s website.
Tewksbury, Mass.-based Corvia said the 100-patient Reduce Lap-HF I study is a prospective, multicenter, randomized controlled trial. The primary ...
Source: Mass Device - March 7, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Implants Cardiovascular Clinical Trials Mergers & Acquisitions Corvia Medical Source Type: news
Regenerative firm Creative Medical launches cardio-focused AngioStem biz
Regenerative biotech company Creative Medical Health said today it is launching a subsidiary biz, AngioStem, to commercialize its cardiovascular assets.
Assets on hand for the newly launched company include a therapy that uses autologous and allogeneic adult stem cells in combination with modulation of oxidative stress to treat heart failure in patients with cardiovascular disease, Creative Medical Health said.
“At Creative Medical Health, our mission is to identify promising technologies, add value by strengthening the science and intellectual property surrounding the technologies, and subsequently spin off new com...
Source: Mass Device - February 29, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiovascular Regenerative Medicine AngioStem Creative Medical Health Source Type: news
MindMaze raises $100m for neural virtual reality platforms
Multisensory computing platform developer MindMaze said today it raised $100 million to support its medical-grade neural virtual reality platforms.
Switzerland-based MindMaze combines virtual reality, computer vision, neuroscience, AI and haptic feedback to create virtual reality rehabilitation platforms and other medical virtual reality applications.
The round was led by the Hinduja Group, and joined by various family offices, the company said.
“MindMaze’s next-generation human-machine interface is already proving itself in healthcare, games, and its potential for applications in transportation, defense and va...
Source: Mass Device - February 17, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Neurological Software / IT MindMaze Source Type: news
Brainlab invests nearly $8m into Jan Medical
Jan Medical said today it obtained $7.5 million in Series C funding from partner Brainlab Inc, with funds slated to aid in completion of a clinical trial and filing for de novo clearance with the FDA and CE Mark approval in the European Union for its BrainPulse tool.
Mountain View, Calif.-based Jan Medical’s BrainPulse device is designed to non-invasively capture novel physiological signals through a patient’s cardiac output, used to measure vascular and brain tissue conditions, the company said. The data can be used as an ‘aid to diagnoses’ for multiple indications, including concussion and stro...
Source: Mass Device - January 25, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiovascular Diagnostics Regulatory/Compliance Brainlab Jan Medical Source Type: news
Mercury Biomed wins $1.4m grant for thermal body tech
Newly formed medical temperature management company Mercury Biomed said Wednesday it won a $1.4 million loan from the Ohio Third Frontier Commercialization Acceleration Loan Fund for its Smart Temperature management system.
The company’s Smart Temperature management system work through applying heat along the back of the neck to send a signal to the body’s thermostat which responds by increasing blood flow on-demand, followed by water-circulating tubes that supply heat or cold to polymeric cooling pads at the hands and feet.
The device uses induced high blood flow between extremities and body cores to accelerat...
Source: Mass Device - December 4, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Mercury Biomed Source Type: news
UPDATE: Embolization coil maker Blockade Medical pulls in $2.2m
UPDATED Oct. 27, 2015, with comment from Blockade Medical.
Blockade Medical pulled in $2.2 million and is looking for another $5.8 million in a new round of equity financing, according to an SEC filing published today.
The round was joined by new investors TitanMed Capital and GP Healthcare Capital, as well as returning investors and other venture capital and private equity funds in the healthcare sector, Blockade Medical said.
Funds from the round will support commercialization efforts for the Barricade coil system, as well as the development of novel neurovascular devices to treat aneurysms, stroke and other conditions,...
Source: Mass Device - October 27, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Vascular Blockade Medical Source Type: news
Procyrion’s Aortix device could heighten heart pump competition
Pay attention to Procyrion over the next several months. CEO Benjamin Hertzog tells MassDevice.com that the company plans on heading to the clinic with a device that could heighten competition among makers of cardiac assist devices.
The Houston-based startup plans to begin 1st-in-human trials of its Aortix catheter-based heart pump in the 1st half of 2016.
Other companies, most notably Abiomed (NSDQ:ABMD), are already in this space. St. Jude Medical (NYSE:STJ) is looking to enter the percutaneous pump market with the HeartMate PHP device it acquired in the $3 billion buyout of Thoratec earlier this fall. Abiomed ...
Source: Mass Device - October 22, 2015 Category: Medical Equipment Authors: Mark Hollmer Tags: Cardiac Assist Devices Abiomed Inc. Procyrion Source Type: news
Silk Road Medical raises $57 million
Silk Road Medical today said it reeled in a $57 million equity-and-debt round from a group of new and existing backers.
Sunnyvale, Calif.-based Silk Road, which makes the Enroute transcarotid artery stent and neuroprotection system, said CRG led the debt round and participated in the equity portion, joined by prior investors Warburg Pincus and The Vertical Group.
“The strength of this financing is a testament to the large opportunity we have to solve unmet clinical needs and lead the next endovascular revolution with TCAR,” CEO Erica Rogers said in prepared remarks. “Our proprietary advances in tempo...
Source: Mass Device - October 20, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Stents Vascular Silk Road Medical Inc. Stroke Source Type: news
Vittamed pulls in $10m Series A for intracranial pressure device
Vittamed said today it raised $10 million in a Series A round of funding to support its intracranial pressure neurodiagnostic sensor development and launch.
The funding round was led by Xeraya Capital Labuan and joined by existing investor Imprimatur Capital and other investors, the Boston-based company said.
“The financial support and expertise of Xeraya Capital will help us accelerate Vittamed’s commercial launch. We are excited about our potential to better diagnose and manage patients with many neurological conditions, including traumatic brain injury, hydrocephalus, stroke, and space occupying lesions incl...
Source: Mass Device - October 16, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Diagnostics Ultrasound Vittamed Source Type: news
Neuravi raises $21m Series B for thrombectomy device
Neuravi said today that it raised $21 million in a Series B round for its Embotrap minimally invasive thrombectomy device.
“The intention of the funding round is to launch the device in Europe, to run the Arise program for the U.S., to attempt to bring the device for U.S. approval and to continue to develop further technologies in the field,” CEO Eamon Brady told MassDevice.com. “One of the things Neuravi has done that’s unique to all of our competition is we have launched a huge research effort over the last 5 years in understanding the properties of clots – the cause of ischemic stroke – an...
Source: Mass Device - June 17, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Blood Management Business/Financial News Cardiovascular Catheters Stents Life Sciences Partners Neuravi Limited Source Type: news
